Global Women’s Health Drugs Market to 2024 – Influx of New Products Including Orilissa, Relugolix and Bremelanotide

Global Women’s Health Drugs Market to 2024 Research Report provides Key Marketed Products, Pipeline Landscape Assessment, Company Analysis and Positioning, Revenue and Market Share and Strategic Consolidations.

Pune, India - February 12, 2019 /MarketersMedia/ —

The women’s health therapy area covers medical disorders that affect females only, primarily disorders of the female reproductive system, including those associated with menstruation, conception, pregnancy, childbirth and menopause. Many of these disorders are highly prevalent among the female population.

The Women’s Health Market is relatively small considering the high prevalence of many women’s health indications. However, robust growth is projected over the forecast period due to the influx of a number of new products.

This report covers all indications within women’s health with a particular focus on five key indications: endometriosis, polycystic ovarian syndrome (PCOS), cervical intraepithelial neoplasia (CIN), menopausal disorders and infertility.

*Company Analysis and Positioning:
Revenue and Market Share Analysis by Company
1 Bayer AG - Company to Remain a Market Leader within Women’s Health
2 AbbVie Inc - Orilissa to Reach Blockbuster Status, Boosting Company’s Market Share
3 Allergan - Revenue Gains From Fibristal, Lo Loestrin Fe and Liletta to Offset Losses from Minastrin 24 Fe and Estrace
4 Merck & Co. - Company to Remain a Key Player Due to Growth of Gardasil/Gardasil 9
5 GlaxoSmithKline - Cervarix and Retosiban to Drive Strong Growth
6 Pfizer - How will patent expiration affect revenues for women’s health market?
7 TherapeuticsMD – Women’s Health Specialist to Gain Considerable Market Share by 2024

Get Discount on Global Women’s Health Drugs Market Research Report at https://www.reportsnreports.com/contacts/discount.aspx?name=1854865

Scope
- There are 277 pipeline products in active development for women’s health disorders. Which molecule types and molecular targets are most prominent within the pipeline?
- Merck&Co and Bayer currently represent leading companies within women’s health. Will they maintain this dominance over the forecast period?
- Gardasil, Mirena and Nuvaring and are among the most lucrative drugs within the women’s health market. Which of these will experience a considerable decline in revenue over the forecast period following loss of patent protection?
- The influx of a number of recent market entrants and late-stage pipeline products will have a considerable impact on the women’s health market over the forecast period. Which of these drugs are projected to achieve blockbuster status by 2024?
- In total, 246 licensing deals relating to women’s health products have been completed since 2006. Which types of assets attracted the largest deal values?

Direct Purchase of this Research Report at https://www.reportsnreports.com/purchase.aspx?name=1854865

Reasons to buy:
- Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
- Analyze the women’s health pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target.
- Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates.
- Predict growth in market size by examining multi-scenario forecasting trends from 2017 to 2024 and determine the contributions that different products and companies will make to this growth.
- Identify commercial opportunities in the women’s health deals landscape by analyzing trends in licensing and co-development deals.

Contact Info:
Name: Vishal Kalra
Email: Send Email
Organization: ReportsnReports
Website: https://www.reportsnreports.com/reports/1854865-global-womens-health-drugs-market-to-2024-influx-of-new-products-including-orilissa-relugolix-and-bremelanotide-to-diversify-landscape-and-drive-growth.html

Source URL: https://marketersmedia.com/global-womens-health-drugs-market-to-2024-influx-of-new-products-including-orilissa-relugolix-and-bremelanotide/481772

Source: MarketersMedia

Release ID: 481772

More News From Technology - Malaysian Talks

Aussie doctors bestowed Thai royal honors for cave rescue

Apr 22, 2019

BANGKOK — Two Australian doctors were given royal honors in Thailand on Friday for helping rescue a boys soccer team from a flooded cave and said they are looking forward to a reunion with the youngsters they helped save. Richard Harris and Craig Challen were given the award at a ceremony presided over by Thai Prime Minister Prayuth Chan-ocha. Four Australian officials involved with the rescue effort were also honored. Both highly skilled divers, the doctors played key roles in rescuing members of the Wild Boars soccer team and their coach from the cave complex in Chiang Rai province last...

Toyota, SoftBank fund, Denso invest $1 billion in Uber

Apr 22, 2019

TOKYO — Japan's top automaker Toyota, auto parts maker Denso and internet company SoftBank's investment fund are investing $1 billion in car-sharing Uber's technology unit. The Japanese companies said Friday that Toyota Motor Corp. and Denso Corp. will together invest $667 million and SoftBank Corp.'s Vision Fund will contribute $333 million in Uber Technologies Inc.'s new entity, Advanced Technologies Group, or Uber ATG, which will try to develop and commercialize automated ridesharing services. The move comes as Toyota steps up such efforts, including investing $500 million in Uber, based in San Francisco, and setting up a $20 million joint venture...

Asian stocks sink after Wall Street declines

Apr 22, 2019

BEIJING — Asian stocks fell Thursday after Wall Street declined despite encouraging Chinese economic data. Benchmarks in Shanghai, Tokyo, Seoul and Hong Kong all retreated. Sydney was little-changed. U.S. stocks fell despite data showing growth in China's gross domestic product held steady in the latest quarter in the face of a tariff war with Washington and consumer spending accelerated. "The surprisingly robust China GDP data failed to ignite a rally on Wall Street as U.S. investors turn focus to domestic concerns," said Stephen Innes of SPI Asset Management in a report. He said investors are "increasingly cautious" about possibly misreading...

Head of Foxconn announces Taiwan presidential bid

Apr 22, 2019

TAIPEI, Taiwan — Terry Gou, chairman of the world's largest contract assembler of consumer electronics, including Apple's iPhones, said Wednesday he intends to run for president of Taiwan, bringing his pro-business and China-friendly policies to what is expected to be a crowded field for next year's election. The Foxconn Technology chairman who also ranks among Taiwan's richest people with a fortune estimated by Forbes at $7.8 billion is seeking the opposition Nationalist Party's nomination for the 2020 presidential race against an incumbent hampered by low public approval ratings. "I am willing to participate in the primary election," Gou said at...

Monkey Punch, creator of megahit Japan comic Lupin III, dies

Apr 22, 2019

TOKYO — Cartoonist Monkey Punch, best known as the creator of the Japanese megahit comic series Lupin III, has died at age of 81. His office, MP Pictures, said Wednesday that Monkey Punch, whose real name is Kazuhiko Kato, died of pneumonia on April 11. The story of master thief Lupin's adventures with his gang — gunman Daisuke Jigen, sword master Goemon Ishikawa and sexy beauty Fujiko Mine, as well as a detective, Zenigata — started in 1967. The cartoon also was adapted for TV animation and movies, some directed by renowned animators including Hayao Miyazaki and Isao Takahata. Kato...